News | Coronavirus (COVID-19) | August 19, 2022

Reduced Myocardial Blood Flow is New Clue in How COVID-19 is Impacting the Heart

A) Patients with prior COVID have higher rates of impaired MFR indicating cardiovascular disease B) Impaired MFR is associated with a higher rate of adverse events in patients with no prior COVID and those with prior COVID

August 19, 2022 —  Patients with prior COVID may be twice as likely to have unhealthy endothelial cells that line the inside of the heart and blood vessels, according to newly published research from Houston Methodist. This finding offers a new clue in understanding covid-19’s impact on cardiovascular health. 

In a new study published today in JACC: Cardiovascular Imaging, Houston Methodist researchers examined the coronary microvasculature health of 393 patients with prior covid-19 infection who had lingering symptoms. This is the first published study linking reduced blood flow in the body and COVID-19

Using a widely available imaging tool, called positron emission tomography (PET), researchers found a 20% decrease in the ability of coronary arteries to dilate, a condition known as microvascular dysfunction. They also found that patients with prior COVID-19 infection were more likely to have reduced myocardial flow reserve – and changes in the resting and stress blood flow – which is a marker for poor prognosis and is associated with a higher risk of adverse cardiovascular events. 

“We were surprised with the consistency of reduced blood flow in post covid patients within the study,” said corresponding author Mouaz Al-Mallah, M.D., director of cardiovascular PET at Houston Methodist DeBakey Heart and Vascular Center, and president elect of the American Society of Nuclear Cardiology. “The findings bring new questions, but also help guide us toward further studying blood flow in COVID-19 patients with persistent symptoms.” 

Dysfunction and inflammation of endothelial cells is a well-known sign of acute Covid-19 infection, but little is known about the long-term effects on the heart and vascular system. Earlier in the pandemic, research indicated that COVID-19 could commonly cause myocarditis but that now appears to be a rare effect of this viral infection. 

A recent study from the Netherlands found that 1 in 8 people had lingering symptoms post-covid. As clinicians continue to see patients with symptoms like shortness of breath, palpations and fatigue after their recovery, the cause of long covid is mostly unknown. 

Further studies are needed to document the magnitude of microvascular dysfunction and to identify strategies for appropriate early diagnosis and management. For instance, reduced myocardial flow reserve can be used to determine a patient’s risk when presenting with symptoms of coronary artery disease over and above the established risk factors, which can become quite relevant in dealing with long Covid. 

Next steps will require clinical studies to discover what is likely to happen in the future to patients whose microvascular health has been affected by COVID-19, particularly those patients who continue to have lingering symptoms, or long COVID. 

This work was supported, in part, by grants from the National Institutes of Health under contract numbers R01 HL133254, R01 HL148338 and R01 HL157790. 

Fr more information: https://www.houstonmethodist.org/ 

Related COVID Content:   

COVID-19 Fallout May Lead to More Cancer Deaths   

Kawasaki-like Inflammatory Disease Affects Children With COVID-19   

FDA Adds Myocarditis Warning to COVID mRNA Vaccine Clinician Fact Sheets   

CMS Now Requires COVID-19 Vaccinations for Healthcare Workers by January 4   

Cardiac MRI of Myocarditis After COVID-19 Vaccination in Adolescents   

Small Number of Patients Have Myocarditis-like Illness After COVID-19 Vaccination   

Overview of Myocarditis Cases Caused by the COVID-19 Vaccine   

Case Study Describes One of the First U.S. Cases of MIS-C   

NIH-funded Project Wants to Identify Children at Risk for MIS-C From COVID-19   


Related Content

News | Cardiac Imaging

July 15, 2025 – Cleerly has announced that EviCore, a leading radiology benefit manager providing coverage guidelines to ...

Home July 16, 2025
Home
News | Cardiac Imaging

July 11, 2025 — Heartflow, Inc. has announced that its Heartflow Plaque Analysis will be included in updated cardiac ...

Home July 15, 2025
Home
News | Cardiac Imaging

July 9, 2025 — Cleerly, a leader in advanced cardiovascular imaging, will be presenting new research at the Society of ...

Home July 15, 2025
Home
News | Cardiac Imaging

Cleerly, a leader in cardiovascular imaging, today announced the promotions of two key executives to expanded leadership ...

Home July 02, 2025
Home
News | Cardiac Imaging

June 25, 2025 — Royal Philips and Methodist Hospitals recently announced the healthcare provider’s strategic investment ...

Home June 25, 2025
Home
News | Cardiac Imaging

June 12, 2025 — GE HealthCare has announced the combination of GE HealthCare’s proprietary features and algorithms with ...

Home June 12, 2025
Home
News | Cardiac Imaging

April 1, 2025 — UltraSight recently announced the presentation at the American College of Cardiology (ACC) Annual ...

Home April 15, 2025
Home
News | Cardiac Imaging

April 3, 2025 — Tower Health and Siemens Healthineers recently announced a 10-year agreement focused on equipment ...

Home April 04, 2025
Home
News | Cardiac Imaging

Pfizer has awarded $80,000 to Rutgers Robert Wood Johnson Medical School (RWJMS) to fund an Amyloidosis Fellowship at ...

Home December 19, 2024
Home
News | Cardiac Imaging

Dec. 11, 2024 — Genetesis, Inc. has launched the CardioFlux Membership program. CardioFlux Membership is designed to be ...

Home December 18, 2024
Home
Subscribe Now